The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
- Registration Number
- NCT00986531
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 59
Inclusion Criteria
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
Exclusion Criteria
- ECT in the last 6 months
- Substance abuse or dependence
- History of claustrophobia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 2 Placebo to match AZD8529 Placebo 1 AZD8529 80 mg AZD8529
- Primary Outcome Measures
Name Time Method Functional magnetic resonance imaging (fMRI) 1 fMRI on Day 4; 1 fMRI on Day 21 Computerized neurocognitive tests 1 on Day -1; 1 on Day 1 and on Day 21
- Secondary Outcome Measures
Name Time Method Positive and Negative Syndrome Scale (PANSS) Day-1; Day 4; Day 17; Day 21 Electroencephalography (EEG) Day 4; Day 21 Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, Labs at screening and on Days -1, 4, 17, 21, and 35; ECG at screening and Day 35; Physical Exam at screening and Day 35; Vital signs at screening and Days -1,4, 17, 21, and 35 Suicidality assessment, collection of adverse events Suicidality assesment at screening; and Days -1, 4, 17, 21, and 35 Adverse events at screening, and Days -1,4,17,21, and 35
Trial Locations
- Locations (1)
Research Site
🇺🇸Philadelphia, Pennsylvania, United States